𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An “all-oral” combination therapy in chronic lymphocytic leukemia including the oral idarubicin

✍ Scribed by Molica, Stefano; Levato, Domenico; Di Renzo, Nicola; La Sala, Antonio; Carotenuto, Mario

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
252 KB
Volume
52
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Etoposide, 6-thioguanine and idarubicin,
Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia
✍ Tapani Ruutu; Erkki Elonen 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB

Twenty patients with advanced acute leukemia (16 acute myeloid leukemia (AML), three myeloid blast crisis (BC) of chronic myeloid leukemia (CML), one acute lymphatic leukemia) were treated with a peroral regimen consisting of etoposide 80 mg/m2 and 6-thioguanine 100 mg/m2 twice daily for 5 days, and

A comparison of the efficacy and safety
A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial
✍ Claire E. Dearden; Sue Richards; Monica Else; Daniel Catovsky; Peter Hillmen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

## Abstract ## BACKGROUND: An oral formulation of fludarabine was introduced for use in chronic lymphocytic leukemia in 2001 following studies demonstrating the bioequivalence of a 40 mg/m^2^ oral dose with a 25 mg/m^2^ intravenous dose. We assessed retrospectively the efficacy of these two routes

Combination therapy with fludarabine and
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Expanding Nilotinib Access in Clinical T
Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH